Veradermics MANE
NYSE MANE
$98.31 +0.56 (+0.57%)
As of: Sep 4, 2026 · 3:59 PM EDT

Veradermics (MANE) Retained Earnings (2024 - 2026)

Veradermics' (MANE) quarterly Retained Earnings came in at -$150.7 million in Q1 2026, down 22.1% on a QoQ basis from -$123.4 million in Q4 2025.

Analysis

Veradermics (MANE) Retained Earnings (2024 - 2026) Analysis & Trends

Veradermics (MANE) has 2 years of Retained Earnings data on file, last reported at -$150.7 million in Q1 2026.

  • Quarterly Retained Earnings changed N/A year-over-year to -$150.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$150.7 million (changed N/A YoY) and the FY2025 annual result came in at -$123.4 million, changed N/A from the prior year.
  • Retained Earnings fell to -$150.7 million in Q1 2026, from -$123.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$123.4 million in Q4 2025 to a low of -$150.7 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 15.69 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 37.62 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 558.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.10 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -4.00 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 13.05 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -6.33 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 4.38 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 6.57 Bn
10 Veradermics 3.96 Bn 3.96 Bn - 989.26 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 989.26 Mn
Mar 31, 2026 543.04 Mn
Dec 31, 2025 -123.42 Mn
Dec 31, 2024 -49.23 Mn